Indefinite Delivery Contract SPE2DR25D9147

The Defense Logistics Agency (DLA) awarded an Indefinite Delivery Contract (IDC) worth up to $4,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, designated SPE2DR25D9147, will run through December 31, 2036 and allows DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. This includes branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. The contract was not set aside for any specific socioeconomic program, enabling DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure this significant single-award IDC with DLA. This contract positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites both domestically and globally.

The IDC was awarded under the DLA's SPE2DB program, which is planning to issue a solicitation in March 2024 to establish Pharmaceutical Prime Vendor Global Program Generation V contracts worth an estimated $30.3 billion. The solicitation will be open for 45 days and is intended to make multiple awards for separate regions, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. Both primary and backup suppliers will provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally.